Table 2 |
||
|
Comparison of clinical features of vitiligo patients with and without anti-thyroid peroxidase antibody |
||
|
Clinical features |
No. (%) with autoantibodies (17 patients) |
No. (%) without autoantibodies (77 patients) |
|
|
||
|
Mean age +/- SD, yr |
26.47 +/-11.52 |
29.16 +/- 16.18 |
|
Gender |
||
|
Male |
5 (10.4) |
43 (89.6) |
|
Female* |
12 (26.1) |
34 (73.9) |
|
Age (year) |
||
|
=>17 |
4 (18.2) |
18 (81.8) |
|
18–25* |
5 (20.8) |
19 (79.2) |
|
26–35* |
5 (18.5) |
22 (81.5) |
|
=<36 |
3 (14.3) |
18 (85.7) |
|
Mean onset age +/- SD,yr |
19.59 +/- 9.5 |
23.59 +/-16.36 |
|
Mean duration +/- SD,yr |
6.88 +/- 9.9 |
5.62 +/- 6.98 |
|
Extent (%) |
||
|
<20 |
12 (17) |
58 (83) |
|
20–50 |
5 (25) |
15 (75) |
|
>50 |
0 |
3 (100) |
|
Type of vitiligo |
||
|
Generalized |
13 (20.6) |
50 (79.4) |
|
Non-generalized |
4 (12.9) |
27 (87.1) |
|
|
||
|
*Difference significant compared with the control group (pv < 0.05) |
||
|
Daneshpazhooh et al. BMC Dermatology 2006 6:3 doi:10.1186/1471-5945-6-3 |
||
